The pharma giant made the announcement post markets hours of Wednesday.

The lawsuit alleged trade secret misappropriation and patent infringement of DUSA's photodynamic therapy patents covering its product.

DUSA has alleged that Biofrontera defendants misappropriated confidential and trade secret information from DUSA and improperly obtained co...

Credit Suisse has upgraded shares of Sun Pharmaceutical Industries to 'outperform' from 'neutral' and raised target price to Rs 925 from Rs...

Its export business, dominated by revenues from the US, is likely to post a revenue increase of around 45 per cent driven by factors like t...

Sun Pharmaceutical Industries is said to be in talks to buy Sweden's pharma firm Meda AB in a deal worth up to $5 billion, according to med...

Taro's Q4 revenue fell sequentially, while local business continued to outperform industry.

Drug maker Sun Pharma's US business continues to drive growth, contributing as it does to over half of the company’s revenues.

Sun Pharma today reported a consolidated net profit of Rs 881.30 crore for the third quarter ended December 31, 2012.

Drug firm Sun Pharmaceutical Industries today said its US-based subsidiary Caraco has successfully completed the tender offer to acquire Du...

Given its past track record, investors can trust the company to go for strategically important acquisitions in its key markets.

With Caraco resuming manufacturing at its facilities in Michigan, the company is likely to gradually recover any loss in revenues.

Sun Pharmaceutical Industries today said it is looking forward to larger acquisitions as a part of its expansion plans.

Shares of Sun Pharma moved higher in trade of Friday as sentiment turned bullish after it signed a pact to buy US-based DUSA Pharmaceutical...

Under the terms of agreement, a 100% subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a pr...

Sun Pharma is to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminole...

In major deals worth Rs 2,850 crore, homegrown companies today announced acquisitions of assets from global firms with Sun Pharma buying DU...